Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspire diquafosol response

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Inspire responds to a December 2003 "approvable" letter for its dry eye agent diquafosol requesting an additional clinical study, the firm announces June 1. "The focus of the NDA amendment is on multiple analyses of ocular surface staining, including corneal staining and conjunctival staining," Inspire said. The company has completed two additional Phase III trials since its initial submission of the P2Y2 receptor agonist in June 2003. The diquafosol pivotal program had mixed results, with one trial failing to show significance versus placebo for the primary endpoint of corneal staining...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel